BOSTON–(BUSINESS WIRE)–Alloy Therapeutics (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today that it is launching a new market-disrupting licensing structure. Partners can now have the option to use the ATX-Gx™ antibody technology platform with no annual access fee or development milestones. Partners benefit from Alloy as an ever-growing source of pre-competitive, foundational discovery technology.

Read more  here.